Hypertension:eGFR预测终点数少于24小时动态血压

2012-11-28 Hypertension Hypertension

  乌拉圭学者的一项研究表明,在普通人群中,估计肾小球率过滤(eGFR)可预测的临床终点少于24小时动态血压(ABP24),并且其为附加性而非倍增性危险因素。论文于2012年11月19日在线发表于《高血压》(Hypertension)杂志。   此项研究从11个人群中随机纳入5322例受试者(中位年龄51.8岁,女性43.1%)。受试者均在基线时测定了ABP24和eGFR。利用多变量校正Cox回

  乌拉圭学者的一项研究表明,在普通人群中,估计肾小球率过滤(eGFR)可预测的临床终点少于24小时动态血压(ABP24),并且其为附加性而非倍增性危险因素。论文于2012年11月19日在线发表于《高血压》(Hypertension)杂志。

  此项研究从11个人群中随机纳入5322例受试者(中位年龄51.8岁,女性43.1%)。受试者均在基线时测定了ABP24和eGFR。利用多变量校正Cox回归模型计算危险比。中位随访时间为9.3年。

  结果显示,随访期间共出现513例死亡,其中心血管性死亡为206例。在包括ABP24和eGFR的完全校正模型中,ABP24可预测总体和心血管性死亡,eGFR则仅可预测心血管性死亡。此外,ABP24可预测心血管疾病、心脏病和卒中所致的致命性和非致命性事件,eGFR则仅可预测心血管复合终点与卒中。ABP24和eGFR之间的交互作用均不具有统计学意义。对于心血管性死亡、心血股复合终点和卒中而言,ABP24可使既往多因素已解释的风险分别增加0.35%、1.17%和1.00%;eGFR则相应增加0.13%、0.09%和0.14%。


Risk Stratification by 24-Hour Ambulatory Blood Pressure and Estimated Glomerular Filtration Rate in 5322 Subjects From 11 Populations

Abstract
No previous study addressed whether in the general population estimated glomerular filtration rate (eGFR [Chronic Kidney Disease Epidemiology Collaboration formula]) adds to the prediction of cardiovascular outcome over and beyond ambulatory blood pressure. We recorded health outcomes in 5322 subjects (median age, 51.8 years; 43.1% women) randomly recruited from 11 populations, who had baseline measurements of 24-hour ambulatory blood pressure (ABP24) and eGFR. We computed hazard ratios using multivariable-adjusted Cox regression. Median follow-up was 9.3 years. In fully adjusted models, which included both ABP24 and eGFR, ABP24 predicted (P≤0.008) both total (513 deaths) and cardiovascular (206) mortality; eGFR only predicted cardiovascular mortality (P=0.012). Furthermore, ABP24 predicted (P≤0.0056) fatal combined with nonfatal events as a result of all cardiovascular causes (555 events), cardiac disease (335 events), or stroke (218 events), whereas eGFR only predicted the composite cardiovascular end point and stroke (P≤0.035). The interaction terms between ABP24 and eGFR were all nonsignificant (P≥0.082). For cardiovascular mortality, the composite cardiovascular end point, and stroke, ABP24 added 0.35%, 1.17%, and 1.00% to the risk already explained by cohort, sex, age, body mass index, smoking and drinking, previous cardiovascular disease, diabetes mellitus, and antihypertensive drug treatment. Adding eGFR explained an additional 0.13%, 0.09%, and 0.14%, respectively. Sensitivity analyses stratified for ethnicity, sex, and the presence of hypertension or chronic kidney disease (eGFR <60 mL/min per 1.73 m2) were confirmatory. In conclusion, in the general population, eGFR predicts fewer end points than ABP24. Relative to ABP24, eGFR is as an additive, not a multiplicative, risk factor and refines risk stratification 2- to 14-fold less.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1636420, encodeId=94d716364202e, content=<a href='/topic/show?id=eb4810160a' target=_blank style='color:#2F92EE;'>#24小时动态血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1016, encryptionId=eb4810160a, topicName=24小时动态血压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa9722636957, createdName=1508842480_96220444, createdTime=Tue Jul 16 05:57:00 CST 2013, time=2013-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725243, encodeId=165a1e25243c9, content=<a href='/topic/show?id=e20b101402' target=_blank style='color:#2F92EE;'>#24小时#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1014, encryptionId=e20b101402, topicName=24小时)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=447433741908, createdName=chengjn, createdTime=Wed Dec 26 13:57:00 CST 2012, time=2012-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038452, encodeId=b6302038452af, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sat Sep 07 09:57:00 CST 2013, time=2013-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725463, encodeId=252d1e254636f, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Oct 10 09:57:00 CST 2013, time=2013-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501008, encodeId=53601501008d1, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Fri Nov 30 00:57:00 CST 2012, time=2012-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508978, encodeId=265f15089e861, content=<a href='/topic/show?id=a7c83311e88' target=_blank style='color:#2F92EE;'>#动态血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33117, encryptionId=a7c83311e88, topicName=动态血压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1e10025437, createdName=limedical1977, createdTime=Fri Nov 30 00:57:00 CST 2012, time=2012-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534200, encodeId=6b571534200ff, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Fri Nov 30 00:57:00 CST 2012, time=2012-11-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1636420, encodeId=94d716364202e, content=<a href='/topic/show?id=eb4810160a' target=_blank style='color:#2F92EE;'>#24小时动态血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1016, encryptionId=eb4810160a, topicName=24小时动态血压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa9722636957, createdName=1508842480_96220444, createdTime=Tue Jul 16 05:57:00 CST 2013, time=2013-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725243, encodeId=165a1e25243c9, content=<a href='/topic/show?id=e20b101402' target=_blank style='color:#2F92EE;'>#24小时#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1014, encryptionId=e20b101402, topicName=24小时)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=447433741908, createdName=chengjn, createdTime=Wed Dec 26 13:57:00 CST 2012, time=2012-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038452, encodeId=b6302038452af, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sat Sep 07 09:57:00 CST 2013, time=2013-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725463, encodeId=252d1e254636f, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Oct 10 09:57:00 CST 2013, time=2013-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501008, encodeId=53601501008d1, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Fri Nov 30 00:57:00 CST 2012, time=2012-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508978, encodeId=265f15089e861, content=<a href='/topic/show?id=a7c83311e88' target=_blank style='color:#2F92EE;'>#动态血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33117, encryptionId=a7c83311e88, topicName=动态血压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1e10025437, createdName=limedical1977, createdTime=Fri Nov 30 00:57:00 CST 2012, time=2012-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534200, encodeId=6b571534200ff, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Fri Nov 30 00:57:00 CST 2012, time=2012-11-30, status=1, ipAttribution=)]
    2012-12-26 chengjn
  3. [GetPortalCommentsPageByObjectIdResponse(id=1636420, encodeId=94d716364202e, content=<a href='/topic/show?id=eb4810160a' target=_blank style='color:#2F92EE;'>#24小时动态血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1016, encryptionId=eb4810160a, topicName=24小时动态血压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa9722636957, createdName=1508842480_96220444, createdTime=Tue Jul 16 05:57:00 CST 2013, time=2013-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725243, encodeId=165a1e25243c9, content=<a href='/topic/show?id=e20b101402' target=_blank style='color:#2F92EE;'>#24小时#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1014, encryptionId=e20b101402, topicName=24小时)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=447433741908, createdName=chengjn, createdTime=Wed Dec 26 13:57:00 CST 2012, time=2012-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038452, encodeId=b6302038452af, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sat Sep 07 09:57:00 CST 2013, time=2013-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725463, encodeId=252d1e254636f, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Oct 10 09:57:00 CST 2013, time=2013-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501008, encodeId=53601501008d1, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Fri Nov 30 00:57:00 CST 2012, time=2012-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508978, encodeId=265f15089e861, content=<a href='/topic/show?id=a7c83311e88' target=_blank style='color:#2F92EE;'>#动态血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33117, encryptionId=a7c83311e88, topicName=动态血压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1e10025437, createdName=limedical1977, createdTime=Fri Nov 30 00:57:00 CST 2012, time=2012-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534200, encodeId=6b571534200ff, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Fri Nov 30 00:57:00 CST 2012, time=2012-11-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1636420, encodeId=94d716364202e, content=<a href='/topic/show?id=eb4810160a' target=_blank style='color:#2F92EE;'>#24小时动态血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1016, encryptionId=eb4810160a, topicName=24小时动态血压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa9722636957, createdName=1508842480_96220444, createdTime=Tue Jul 16 05:57:00 CST 2013, time=2013-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725243, encodeId=165a1e25243c9, content=<a href='/topic/show?id=e20b101402' target=_blank style='color:#2F92EE;'>#24小时#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1014, encryptionId=e20b101402, topicName=24小时)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=447433741908, createdName=chengjn, createdTime=Wed Dec 26 13:57:00 CST 2012, time=2012-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038452, encodeId=b6302038452af, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sat Sep 07 09:57:00 CST 2013, time=2013-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725463, encodeId=252d1e254636f, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Oct 10 09:57:00 CST 2013, time=2013-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501008, encodeId=53601501008d1, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Fri Nov 30 00:57:00 CST 2012, time=2012-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508978, encodeId=265f15089e861, content=<a href='/topic/show?id=a7c83311e88' target=_blank style='color:#2F92EE;'>#动态血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33117, encryptionId=a7c83311e88, topicName=动态血压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1e10025437, createdName=limedical1977, createdTime=Fri Nov 30 00:57:00 CST 2012, time=2012-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534200, encodeId=6b571534200ff, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Fri Nov 30 00:57:00 CST 2012, time=2012-11-30, status=1, ipAttribution=)]
    2013-10-10 feather89
  5. [GetPortalCommentsPageByObjectIdResponse(id=1636420, encodeId=94d716364202e, content=<a href='/topic/show?id=eb4810160a' target=_blank style='color:#2F92EE;'>#24小时动态血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1016, encryptionId=eb4810160a, topicName=24小时动态血压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa9722636957, createdName=1508842480_96220444, createdTime=Tue Jul 16 05:57:00 CST 2013, time=2013-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725243, encodeId=165a1e25243c9, content=<a href='/topic/show?id=e20b101402' target=_blank style='color:#2F92EE;'>#24小时#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1014, encryptionId=e20b101402, topicName=24小时)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=447433741908, createdName=chengjn, createdTime=Wed Dec 26 13:57:00 CST 2012, time=2012-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038452, encodeId=b6302038452af, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sat Sep 07 09:57:00 CST 2013, time=2013-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725463, encodeId=252d1e254636f, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Oct 10 09:57:00 CST 2013, time=2013-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501008, encodeId=53601501008d1, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Fri Nov 30 00:57:00 CST 2012, time=2012-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508978, encodeId=265f15089e861, content=<a href='/topic/show?id=a7c83311e88' target=_blank style='color:#2F92EE;'>#动态血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33117, encryptionId=a7c83311e88, topicName=动态血压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1e10025437, createdName=limedical1977, createdTime=Fri Nov 30 00:57:00 CST 2012, time=2012-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534200, encodeId=6b571534200ff, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Fri Nov 30 00:57:00 CST 2012, time=2012-11-30, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1636420, encodeId=94d716364202e, content=<a href='/topic/show?id=eb4810160a' target=_blank style='color:#2F92EE;'>#24小时动态血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1016, encryptionId=eb4810160a, topicName=24小时动态血压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa9722636957, createdName=1508842480_96220444, createdTime=Tue Jul 16 05:57:00 CST 2013, time=2013-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725243, encodeId=165a1e25243c9, content=<a href='/topic/show?id=e20b101402' target=_blank style='color:#2F92EE;'>#24小时#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1014, encryptionId=e20b101402, topicName=24小时)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=447433741908, createdName=chengjn, createdTime=Wed Dec 26 13:57:00 CST 2012, time=2012-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038452, encodeId=b6302038452af, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sat Sep 07 09:57:00 CST 2013, time=2013-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725463, encodeId=252d1e254636f, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Oct 10 09:57:00 CST 2013, time=2013-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501008, encodeId=53601501008d1, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Fri Nov 30 00:57:00 CST 2012, time=2012-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508978, encodeId=265f15089e861, content=<a href='/topic/show?id=a7c83311e88' target=_blank style='color:#2F92EE;'>#动态血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33117, encryptionId=a7c83311e88, topicName=动态血压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1e10025437, createdName=limedical1977, createdTime=Fri Nov 30 00:57:00 CST 2012, time=2012-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534200, encodeId=6b571534200ff, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Fri Nov 30 00:57:00 CST 2012, time=2012-11-30, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1636420, encodeId=94d716364202e, content=<a href='/topic/show?id=eb4810160a' target=_blank style='color:#2F92EE;'>#24小时动态血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1016, encryptionId=eb4810160a, topicName=24小时动态血压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa9722636957, createdName=1508842480_96220444, createdTime=Tue Jul 16 05:57:00 CST 2013, time=2013-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725243, encodeId=165a1e25243c9, content=<a href='/topic/show?id=e20b101402' target=_blank style='color:#2F92EE;'>#24小时#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1014, encryptionId=e20b101402, topicName=24小时)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=447433741908, createdName=chengjn, createdTime=Wed Dec 26 13:57:00 CST 2012, time=2012-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038452, encodeId=b6302038452af, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sat Sep 07 09:57:00 CST 2013, time=2013-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725463, encodeId=252d1e254636f, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Oct 10 09:57:00 CST 2013, time=2013-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501008, encodeId=53601501008d1, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Fri Nov 30 00:57:00 CST 2012, time=2012-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508978, encodeId=265f15089e861, content=<a href='/topic/show?id=a7c83311e88' target=_blank style='color:#2F92EE;'>#动态血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33117, encryptionId=a7c83311e88, topicName=动态血压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1e10025437, createdName=limedical1977, createdTime=Fri Nov 30 00:57:00 CST 2012, time=2012-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534200, encodeId=6b571534200ff, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Fri Nov 30 00:57:00 CST 2012, time=2012-11-30, status=1, ipAttribution=)]
    2012-11-30 liuyiping